Mood disorders: pharmacologic prevention of recurrences. A National Institutes of Health consensus report synopsis.
作者信息
Hull R H
出版信息
Indiana Med. 1985 Jan;78(1):36-7.
PMID:3968418
Abstract
摘要
相似文献
1
2
3
Mood disorders: pharmacologic prevention of recurrences. National Institutes of Health Consensus Development Conference Statement.情绪障碍：复发的药物预防。美国国立卫生研究院共识发展会议声明
Natl Inst Health Consens Dev Conf Consens Statement. 1984;5(4):8 p..
4
NIMH/NIH Consensus Development Conference statement. Mood disorders: pharmacologic prevention of recurrences. Consensus Development Panel.美国国立精神卫生研究所/美国国立卫生研究院共识发展会议声明。情绪障碍：复发的药物预防。共识发展小组。
Am J Psychiatry. 1985 Apr;142(4):469-76. doi: 10.1176/ajp.142.4.469.
5
Prophylactic lithium treatment: treatment response, and patient attitudes toward illness and treatment.
Pharmacopsychiatry. 1988 Nov;21(6):274-5. doi: 10.1055/s-2007-1016973.
6
[Mechanism and clinical effects of drugs for mood disorder].
Ryoikibetsu Shokogun Shirizu. 2003(38):358-61.
7
8
[Pseudo-schizophrenic forms of mood disorders].[心境障碍的假性精神分裂症形式]
Ann Med Psychol (Paris). 1991 Oct;149(8):649-56; discussion 656-7.
9
Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.血清素转运体基因与心境障碍锂盐预防性治疗之间可能存在关联的进一步证据。
Pharmacogenomics J. 2004;4(4):267-73. doi: 10.1038/sj.tpj.6500252.
10
[Prophylactic treatment of mood disorders: cost effectiveness analysis comparing lithium and carbamazepine].
Encephale. 1999 Sep-Oct;25(5):391-400.
Zotero 插件